Orgalutran (Ganirelix)

Ganirelix is a competitive antagonist of gonadotropin‑releasing hormone (GnRH) receptors on the pituitary gland. By blocking GnRH binding, it rapidly reduces the secretion of LH and follicle‑stimulating hormone (FSH), thereby preventing the natural LH surge that would otherwise cause premature ovulation during ovarian stimulation.

The specific dose of Orgalutran is determined by the treating physician based on the individual’s ovarian response, stimulation protocol, and monitoring results. Clinicians typically start with a standard dosing schedule and may adjust the amount or timing according to ultrasound and hormone measurements.

Ganirelix is not intended for use during an established pregnancy, and treatment is stopped if pregnancy is confirmed. Safety data for use while breastfeeding are limited; therefore, the medication is generally avoided during lactation unless the benefits outweigh potential risks as judged by a healthcare professional.

To order Orgalutran, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials. The sales team then replies with pricing, availability, shipping details (including cold‑chain handling if needed) and any required import documentation.

The primary alternative to Orgalutran is another GnRH antagonist, cetrorelix, which works by the same receptor‑blocking mechanism. Compared with GnRH agonists, antagonists like ganirelix provide a more immediate suppression of LH without the initial flare effect, allowing a shorter and more flexible stimulation protocol.

Orgalutran should be stored at 2‑8 °C (refrigerated) in its original packaging, protected from light. It must not be frozen or shaken. If temporary temperature excursions occur, the product should be inspected for clarity and used only if it remains within specifications.

Orgalutran is administered as a subcutaneous injection, typically in the abdominal wall or thigh. The injection is given once daily during the controlled ovarian stimulation phase, starting after the initial gonadotropin dose and continuing until the trigger for final oocyte maturation is administered.

The most serious risks include ovarian hyperstimulation syndrome (OHSS), which can be severe and require hospitalization, and rare allergic reactions such as anaphylaxis. Patients should also be monitored for signs of thromboembolic events or severe abdominal pain, and any concerning symptoms should prompt immediate medical evaluation.

Orgalutran should be avoided in individuals with known hypersensitivity to ganirelix or any of its excipients. It is also contraindicated in patients with active ovarian cysts that could be exacerbated by stimulation, and it should not be used during an established pregnancy. Clinicians must assess each patient’s medical history before prescribing.